The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as ...

NB.1.8.1 is one of the latest variants of COVID-19, a "slightly upgraded version" of the LP.8.1 variant that is prominent ...

After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety ...

The Moderna vaccine is one of the vaccines currently available in the United States and other countries to protect against COVID-19, which is the disease the novel coronavirus causes. Clinical ...

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

(HealthDay News) — The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

Among the participants in the present study, 972 developed acute kidney injury, with 411 (42.3%) unvaccinated and 467 (48%) ...